Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2008 monograph topics are on alvimopan, tolvaptan, liraglutide, iclaprim injection, and alogliptin. The DUE is on alvimopan.
Get full access to this article
View all access options for this article.
References
1.
Treximet [package insert].Research Triangle Park, NC: GlaxoSmithKline; April 2008.
2.
KoriS., LittlefieldD., TaylorD., WarginB., HabererL., LenerS.Pharmacokinetics of a single-tablet formulation of sumatriptan RT Technology and naproxen sodium [abstract]. Cephalalgia.2005; 25(2): 933.
3.
LandyS., DeRossettS.E., RapoportA.Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed.2007; 9(2): 53.
4.
Naproxen and Triptan. Drug Facts and Comparisons. factsandcomparisons4.0 [online]. 2008. Available from Wolters Kluwer Health, Inc. Accessed April 17, 2008.
5.
ByrdS., DollW., KoriS., PageR., SandeferE.Gastric emptying and absorption of a sumatriptan with RT Technology 85 mg and naproxen sodium 500 mg tablet [abstract]. Cephalalgia.2007; 27(6): 649.
6.
AlexanderW.J., LittlefieldD., TaylorD., WarginB., HabererL., LenerS.The effect of food, migraine and a second tablet on the pharmacokinetic profile of a single tablet combining sumatriptan RT Technology and naproxen sodium for the acute treatment of migraine [abstract]. Cephalalgia.2005; 25: 932.
7.
ByrdS., DeRosierF., GuillardF.PK and cardiovascular effects of a single tablet of sumatriptan RT 85 mg/naproxen sodium 500 mg vs sumatriptan RT 100 mg [abstract]. Cephalalgia.2007; 27(6): 724.
8.
WallsC., ByrdS., HickmottF.Early sumatriptan pharmacokinetics following a sumatriptan 100 mg RT Technology tablet and a fixed single-tablet formulation of sumatriptan 85 mg RT Technology and 500 mg naproxen sodium [abstract]. Cephalalgia.2006; 26: 1395.
9.
SrinivasuP., RambhauD., RaoB.R., RaoY.M.Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol.2000; 40(1): 99–104.
10.
BrandesJ.L., KudrowD., StarkS.R.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA.2007; 297(13): 1443–1454.
11.
AdelmanJ., AuroraS., LenerS., LiptonR., NelsenA., WhiteJ.Within person consistency across 4 migraine attacks of sumatriptan 85 mg RT Technology and naproxen sodium 500 mg [abstract]. Cephalalgia.2007; 27(6): 758.
12.
DodickD., KanieckiR., KoriS., MathewsN., McDonaldS., NelsenA.Incidence and responsiveness of traditional and non-traditional migraine-associated symptoms [abstract]. Cephalalgia.2007; 27(6): 728.
13.
BurchS.P., CadyR., GoldsteinJ., O'DonnellF., RunkenM.C.Consistent medication satisfaction with sumatriptan RT Technology and naproxen for acute migraine treatment [abstract]. Cephalalgia.2007; 27(6): 702.
14.
LandyS., FreitagF., SmithT., BurchS., WhiteJ.D., RunkenM.C.Assessing workplace productivity and activity time in migraineurs treated with a single-tablet of sumatriptan formulated with RT Technology and naproxen sodium (SumaRT/NAP) or placebo [abstract]. Neurology.2007; 68(12): A265.
15.
SheftellF., WinnerP., FinkelA., LenerS., WhiteJ., NelsenA.Consistent sustained efficacy across 4 migraine attacks with a fixed single-tablet formulation of sumatriptan 85 mg RT Technology and naproxen sodium 500 mg (SumaRT/Nap) [abstract]. Headache.2007; 47(5): 769.
16.
SilbersteinS., GoldsteinJ., MannixL.K.A new migraine therapy: efficacy and tolerability of a fixed single-tablet formulation of sumatriptan RT Technology and naproxen sodium in the early intervention paradigm [abstract]. Headache.2006; 46(5): 858.
17.
WinnerP., CadyR.K., RuoffG.E.Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc.2007; 82(1): 61–68.
18.
SmithT., BlumenthalH., DiamondM.Sumatriptan/naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache.2007; 47(5): 683–692.
19.
MannixL.K., CadyR., DiamondM.I.Efficacy and tolerability of a fixed single-tablet formulation of sumatriptan RT Technology and naproxen sodium in menstrual migraine in women with dysmenorrhea [abstract]. Headache.2007; 47(5): 784.
20.
DiamondM., MartinV., BallardJ.Patient satisfaction following treatment of a menstrually-related migraine and dysmenorrhea with a single-tablet formulation of sumatriptan RT Technology and naproxen sodium [abstract]. Headache.2007; 47(5): 786.
21.
CadyR., MannixL., DiamondM.Work productivity and disability in menstrually-related migraines and dysmenorrhea following treatment with a single-tablet formulation of sumatriptan RT Technology and naproxen sodium [abstract]. Headache.2007; 47(5): 788.
22.
SmithT.R., SunshineA., StarkS.R., LittlefieldD.E., SpruillS.E., AlexanderW.J.Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache.2005; 45(8): 983–991.
23.
KrymchantowskiA.V.Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr.2000; 58(2B): 428–430.
